Developments in renal pharmacogenomics and applications in chronic kidney disease

Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors linked with CKD evolution are distinguished, it will be possible to provide and enhance a more intensive treatment to high-risk patients. In this review, we focus on the emerging markers that might be predictive or related to CKD progression physiopathology as well as those related to a different pattern of response to treatment, such as inhibitors of the renin–angiotensin system (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; the vitamin D receptor agonist; salt sensitivity hypertension; and progressive kidney-disease markers with identified genetic polymorphisms). Candidate-gene association studies and genome-wide association studies have analyzed the genetic basis for common renal diseases, including CKD and related factors such as diabetes and hypertension. This review will, in brief, consider genotype-based pharmacotherapy, risk prediction, drug target recognition, and personalized treatments, and will mainly focus on findings in CKD patients. An improved understanding will smooth the progress of switching from classical clinical medicine to gene-based medicine.

• Publication year

  2014

• Venue

  Pharmacogenomics and Personalized Medicine

• Publication date

  2014-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/PGPM.S52763PMID 25206311PMCID 4157401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.

  2014influential reference
• Hypertension in developing countries.

  2014cited by this paper
• Chronic kidney disease: global dimension and perspectives

  2013cited by this paper
• Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease: A Case-Control Study

  2013cited by this paper
• Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study

  2013cited by this paper
• Association of rs1800471 polymorphism of TGFB1 gene with chronic kidney disease occurrence and progression and hypertension appearance

  2013cited by this paper
• Association of CYP1A1 gene polymorphism with chronic kidney disease: a case control study.

  2013cited by this paper
• A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese.

  2013cited by this paper
• Chronic kidney disease in general populations and primary care: diagnostic and therapeutic considerations

  2013cited by this paper
• APOL1 risk variants, race, and progression of chronic kidney disease.

  2013cited by this paper
• Association of chemokine gene variants with end stage renal disease in North Indian population.

  2013cited by this paper
• Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients.

  2013cited by this paper
• Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort.

  2013cited by this paper
• [Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients].

  2013cited by this paper
• Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.

  2012cited by this paper
• Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary study

  2012cited by this paper
• eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril

  2012cited by this paper
• What do we know about chronic kidney disease in India: first report of the Indian CKD registry

  2012cited by this paper
• New hope or drawbacks: will chronic kidney disease be treatable with small molecules in the near future?

  2012cited by this paper
• Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications.

  2012cited by this paper
• Hypertension in developing countries.

  2012cited by this paper
• Meta‐analysis of the relationship between ACE I/D gene polymorphism and end‐stage renal disease in patients with diabetic nephropathy

  2012cited by this paper
• Screening for Chronic Kidney Disease: Preventing Harm or Harming the Healthy?

  2012cited by this paper
• Genetic studies in chronic kidney disease: interpretation and clinical applicability.

  2012cited by this paper
• Treatment of chronic kidney disease.

  2012cited by this paper
• Sodium intake, ACE inhibition, and progression to ESRD.

  2012cited by this paper
• Global Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease

  2012cited by this paper
• Association of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: a meta-analysis

  2012cited by this paper
• Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans.

  2012cited by this paper
• Polymorphisms in the Non-Muscle Myosin Heavy Chain Gene (MYH9) Are Associated with Lower Glomerular Filtration Rate in Mixed Ancestry Diabetic Subjects from South Africa

  2012cited by this paper
• The genetics of common kidney disease: a pathway toward clinical relevance

  2011cited by this paper
• Genetics of Salt-Sensitive Hypertension

  2011cited by this paper
• Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy.

  2011cited by this paper
• Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients

  2011cited by this paper
• Cytochromes P450 are essential players in the vitamin D signaling system.

  2011cited by this paper
• Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

  2011cited by this paper
• Vitamin D deficiency, vitamin D receptor gene polymorphisms and cardiovascular risk factors in Caribbean patients with type 2 diabetes.

  2011cited by this paper
• 1α,25-Dihydroxyvitamin D3 Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Both fxr(−/−) and fxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo

  2011cited by this paper
• Relationship between CYP1A1 genetic polymorphisms and renal cancer in China.

  2011cited by this paper
• Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine

  2011cited by this paper
• Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

  2011cited by this paper
• Genetic epidemiology of induced CYP3A4 activity

  2011cited by this paper
• Genomics and drug response.

  2011cited by this paper
• Nuclear receptors in renal disease.

  2011cited by this paper
• Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

  2011cited by this paper
• Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis.

  2011cited by this paper
• Beyond genetics: epigenetic code in chronic kidney disease.

  2011cited by this paper
• Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications.

  2011cited by this paper
• The MYH9/APOL1 region and chronic kidney disease in European-Americans.

  2011cited by this paper
• Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption

  2011cited by this paper
• Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis.

  2010cited by this paper
• Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations.

  2010cited by this paper
• Prevalence of chronic renal disease in Spain: results of the EPIRCE study.

  2010cited by this paper
• Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans

  2010cited by this paper
• Association of Trypanolytic ApoL 1 Variants with Kidney Disease in African Americans

  2010cited by this paper
• Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis

  2010cited by this paper
• Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease

  2010cited by this paper
• Methylation determines fibroblast activation and fibrogenesis in the kidney

  2010cited by this paper
• Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis

  2010cited by this paper
• Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

  2010cited by this paper
• Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review.

  2010cited by this paper
• The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

  2010cited by this paper
• Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

  2010cited by this paper
• African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans

  2010cited by this paper
• The RAAS in the pathogenesis and treatment of diabetic nephropathy

  2010influential reference
• Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene

  2010cited by this paper
• Chronic kidney disease associated with environmental toxins and exposures.

  2010cited by this paper
• A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.

  2010cited by this paper
• New loci associated with kidney function and chronic kidney disease

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease

  2010cited by this paper
• TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.

  2010cited by this paper
• Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1

  2009cited by this paper
• Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD.

  2009cited by this paper
• Emerging risk factors and markers of chronic kidney disease progression

  2009cited by this paper
• Low serum testosterone increases mortality risk among male dialysis patients.

  2009cited by this paper
• CCR5 deletion protects against inflammation-associated mortality in dialysis patients.

  2009cited by this paper
• Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

  2009cited by this paper
• Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension

  2009cited by this paper
• Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer

  2009cited by this paper
• Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes.

  2009cited by this paper
• CYP3A5 and ABCB1 genes and hypertension.

  2009cited by this paper
• GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients.

  2009cited by this paper
• Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

  2009influential reference
• Statin regulation of CYP3A4 and CYP3A5 expression.

  2009cited by this paper
• Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.

  2008influential reference
• Identification of the functional vitamin D response elements in the human MDR1 gene.

  2008cited by this paper
• Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.

  2008cited by this paper
• [Prevalence of chronic kidney disease].

  2008cited by this paper
• Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis.

  2008cited by this paper
• ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

  2008cited by this paper
• Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians.

  2008cited by this paper
• Impact of activated vitamin D and race on survival among hemodialysis patients.

  2008cited by this paper
• Carrier screening for spinal muscular atrophy

  2008cited by this paper
• MYH9 is associated with nondiabetic end-stage renal disease in African Americans

  2008cited by this paper
• Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

  2008cited by this paper
• Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial

  2008cited by this paper
• Relationship between chronic kidney disease prevalence and end-stage renal disease risk

  2008cited by this paper
• Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury.

  2008cited by this paper
• Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.

  2008cited by this paper

• Contemporary Perspectives on Chronic Renal Disorders

  2025cites this paper
• Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review

  2023cites this paper
• The in vitro/in vivo metabolic pathways analysis of lobetyol, lobetyolin, and lobetyolinin, three polyacetylenes from Codonopsis Radix, by UHPLC-Q/TOF-MS and UHPLC-MS/MS.

  2022cites this paper
• Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy

  2020cites this paper
• GENETIC PREDICTORS OF THE CHRONIC HEART FAILURE DEVELOPMENT AND PROGRESSION: THE ROLE OF POLYMORPHIC GENES

  2019cites this paper
• Quantitative Modeling and Optimal Control of Immunosuppressant Treatment Dynamics in Renal Transplant Recipients.

  2018cites this paper
• Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change

  2018cites this paper
• Chronic Kidney Disease: Overview

  2017cites this paper
• Drug-Induced Kidney Disease

  2017cites this paper
• Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases

  2017cites this paper
• Molecular Biological Markers for Toxicology and Risk Assessment

  2016cites this paper
• Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana

  2015cites this paper
• Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children

  2015cites this paper
• Shen-Kang protects 5/6 nephrectomized rats against renal injury by reducing oxidative stress through the MAPK signaling pathways

  2015cites this paper